Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells

(2010) Sudharsan Periyasamy-Thandavan et al.   Autophagy

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

Regulation of Apoptotic and Inflammatory Cell Signaling in Cerebral Ischemia

(2009) Rona G. Giffard et al.   ANESTHESIOLOGY

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

(2009) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition

(2009) Katerina Oikonomopoulou et al.   CLINICAL BIOCHEMISTRY

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent

(2009) Britt Erika Hanson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90

(2009) Charles Erlichman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Heat Shock Protein 90: Inhibitors in Clinical Trials

(2009) Marco A. Biamonte et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

(2009) Hongjuan Dong et al.   LEUKEMIA & LYMPHOMA

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

(2009) K. Lundgren et al.   MOLECULAR CANCER THERAPEUTICS

Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma

(2009) Jean-Luc Harousseau et al.   NEW ENGLAND JOURNAL OF MEDICINE

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

(2008) Y. Okawa et al.   BLOOD

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

(2008) D. B. Solit et al.   CLINICAL CANCER RESEARCH

Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment

(2008) A. Huston et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

(2008) E. I. Heath et al.   CLINICAL CANCER RESEARCH

144 POSTER XL888, a novel, synthetic, orally bioavailable inhibitor of Hsp90

(2008) M. Nicoll   EJC SUPPLEMENTS

150 POSTER MPC-3100: A non-natural product Hsp90 inhibitor with anti-tumor activity in pre-clinical models

(2008) D. Wettstein et al.   EJC SUPPLEMENTS

153 POSTER IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class

(2008) J. Lee et al.   EJC SUPPLEMENTS

147 POSTER AT13387, a fragment derived clinical candidate is active in lung and melanoma models

(2008) J. Lyons et al.   EJC SUPPLEMENTS

152 POSTER Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat

(2008) Z. Zhong et al.   EJC SUPPLEMENTS

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

(2008) Tzu-Yin Lin et al.   EXPERIMENTAL HEMATOLOGY

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

(2008) T Stühmer et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE